bined with granulocyte colony-stimulating factor (G-CSF) is one of the commonly used regimens for progenitor cell mobilisation although a variety of standard chemotherapy regimens have been used successfully. 5, 6 The effects of these chemotherapeutic drugs, given as part of a mobilisation regimen or in previous cycles of chemotherapy, on progenitor cell viability and apoptosis are unknown. In lymphoma patients, who were heavily pretreated, significantly lower numbers of progenitor cells were collected despite the use of G-CSF to improve mobilisation. 7 Other studies have reported age, previous radiation and chemotherapy treatment on the failure to mobilise PBSC in breast cancer, lymphoma and myeloma. 8, 9 Apoptosis or programmed cell death has an important role in maintaining cellular homeostasis in differentiated haematopoietic cells. Certain changes which occur in haematopoietic progenitor cells as they differentiate including down regulation of bcl-2 protein synthesis and increased expression of Fas antigen (CD95) on the cell surface, have been linked to an increase in apoptosis. 10 These changes in progenitor cells may also indicate a significant loss of their self-renewal capacity.
One of the major problems in quantifying apoptosis is the lack of a simple technique to measure apoptosis on a per cell basis. Classical techniques to detect apoptosis used light microscopy to identify morphologic changes; flow cytometry with non-vital dyes to analyse nuclear staining, cell size and DNA ploidy; gel electrophoresis of DNA fragments to visualise a typical DNA 'ladder' resulting from endonuclease cleavage. [11] [12] [13] These techniques are time-consuming, subjective and do not offer themselves to simple quantitation of apoptotic cells. Although flow cytometry using non-vital dyes is quantifiable, it is based on loss of membrane permeability and is not specific to the apoptotic process.
14 Recently two flow cytometry techniques have been described which overcome this problem by using nonpermeabilised cells. Staining cells with the fluorescent DNA-binding agent, 7-amino-actinomycin D (7-AAD), identified three separate populations of dead, apoptotic and live cells. 15 A second technique uses fluorescein-labeled annexin V to identify early apoptotic cells. 16 Annexin V binds to phosphatidylserine which is abnormally exposed on the outer cell membrane during spatial changes that occur in membrane phospholipid symmetry in the early stages of apoptosis. 17 Viable cells were negatively stained by annexin V-fluorescein isothiocyanate (FITC).
With the advantages of simple preparation and 'real time' analysis, flow cytometry is used increasingly to quantify progenitor cell populations in PBSC harvests. This has replaced established methods of clonogenic culture (colony-forming unit granulocyte-macrophage (CFU-GM)). Despite its increased accuracy and reproducibility by the use of commercial reagents, flow cytometry has not established a consensus on the quality of the progenitor cells used for transplantation. If clonogenic techniques are to be completely replaced, additional factors need to be analysed by flow cytometry. In this study, we examined apoptosis in progenitor cells from PBSC harvests immediately after apheresis using two colour flow cytometry and compared it to colony formation (CFU-GM).
Materials and methods

Patients
Thirty autologous PBSC harvests collected from 16 patients were studied. Five patients had non-Hodgkin's lymphoma (NHL), four Hodgkin's disease (HD), three acute myeloid leukaemia (AML), two acute lymphoblastic leukaemia (ALL), one chronic myeloid leukaemia (CML), and one had Poems syndrome. PBSC were mobilised using one of the following regimens; CY (2.5 g/m 2 ) + G-CSF (300 g/day); standard chemotherapy + G-CSF; standard chemotherapy alone; steady state administration of G-CSF. PBSC harvests were collected on either a Cobe Spectra (Cobe Laboratories, Gloucester, UK) or Baxter CS3000 cell separators (Baxter Healthcare, Newbury, UK) into citrated autologous plasma. On average, 9 litres of blood were processed during each procedure at approximately 3 l/h. In some patients, harvests collected on consecutive days were analysed. Informed consent was given by all patients and the study was approved by Lothian Research Ethics Committee.
Flow cytometry
Cells were obtained directly from the apheresis product at the end of harvesting before they were cryopreserved. An aliquot of cells (1 × 10 6 ) was washed in phosphate-buffered saline (PBS), incubated 15 min at 4°C with phycoerythrin (PE)-conjugated monoclonal antibody (MoAb) to CD34 (HPCA-2; Becton Dickinson, Oxford, UK) and washed three times with PBS. The cells were resuspended in 1 ml annexin buffer (10 mmol/l Hepes/NaOH pH 7.4, 150 mmol/l NaCl, 5 mmol/l KCl, 1 mmol/l MgCl 2 , 1.8 mmol/l CaCl 2 ) and FITC-conjugated recombinant annexin V (Biowhittaker, Berks, UK) added to a final concentration of 1 mg/ml.
14 The cells were incubated for 5 min at 4°C, washed and analysed on a FACSCaliber flow cytometer (Becton Dickinson). Fluorescence compensation on the flow cytometer was adjusted to minimise overlap of the FITC and PE signals. A total of 50 000 events were acquired on five parameters for each sample and analysed using CellQuest software. PE-conjugated isotype-matched MoAb was used as negative control. Mononuclear cells (MNC) from 10 healthy volunteers were prepared by ficoll/metrizoate (Nycomed, Oslo, Norway) density gradient centrifugation of freshly collected peripheral blood and stained with annexin V FITC and propidium iodide (PI, final concentration 50 mg/ml) to obtain control values for annexin V binding.
Clonogenic assay
The concentration of progenitor cells in the apheresis product was determined using a semisolid clonogenic culture assay (CFU-GM). Cells (2 × 10 5 ) from the apheresis product were cultured directly after collection in Iscove's modified Dulbecco's medium (IMDM) supplemented with 30% foetal calf serum (FCS), 10% conditioned medium from a bladder carcinoma cell line 5637, 10 −4 m 2-mercaptoethanol (ME), and 0.9% methyl cellulose. After 14 days culture at 37°C in 5% CO 2 in air, colonies composed of more than 40 cells were scored as GM colonies. Results were expressed as CFU-GM/10 5 mononuclear cells (MNC).
Statistics
The data was analysed by a two sample t-test with a 95% confidence interval.
Results
We Figure 1a and b. Quadrants were set to define the maximum fluorescence intensity for background staining by annexin V. Test samples with higher levels of annexin V binding were considered positive and apoptotic. For twocolour analysis, CD34
+ cells were first gated on side-scatter and fluorescence characteristics, and the gated population analysed for annexin V fluorescence (Figure 1c-f) . The mean percentage of CD34 + cells in the harvests was 3.36 ± 5.71%. Of the CD34 + cells, 80.40 ± 17.32% were annexin V−. On average at least one in five CD34
+ progenitor cells from PBSC harvests were shown to be apoptotic by staining with annexin V FITC. In only 14/30 (47%) PBSC harvests studied was there a low level (less than 10%) of annexin V+ cells within the CD34 + population and in 3/30 (10%) harvests more than 50% of the CD34 + cells were annexin V+. In a patient with AML, the harvest was Results are expressed as mean ± standard deviation.
contaminated by a high proportion of CD34 + blast cells, 96.5% of these were annexin V−.
In nine patients, harvests collected on 2 consecutive days were analysed (Table 1) . Harvests collected on days 1 and 2 gave different results depending upon the technique used to quantify the progenitor cell population. Flow cytometry found similar levels of CD34 + cells in the day 1 and day 2 harvests (6.24 vs 5.06 × 10 6 /kg) whereas the number of CFU-GM collected was considerably higher in the day 2 harvest (16.03 vs 28.44 × 10 4 /kg). This difference was not statistically significant (P = 0.23). A significant difference was observed in the number of CD34 + cells that were annexin V−. There was a lower percentage of annexin V− progenitor cells in the first harvest (71.9 vs 88.3%, P = 0.03), therefore these contained a higher proportion of apoptotic CD34
+ cells than was found in the second harvest. PBSC harvests were compared from two groups of patients who received either CY + G-CSF or standard chemotherapy + G-CSF as part of their mobilising regimen (Table 2) . Patients who were given CY + G-CSF had PBSC harvests with significantly higher collections of CD34 + cells that were annexin V+ was not significantly different between the two groups.
Discussion
In this report, we describe a simple technique using flow cytometry to quantify apoptosis by annexin V binding to cells obtained from PBSC harvests. Annexin V binds specifically to phosphatidylserine expressed on the outer cell membrane of apoptotic cells. Viable cells have a normal cell membrane phospholipid symmetry and do not bind annexin V. Apoptosis is characterised by chromatin con- Table 2 Comparison of PBSC harvests mobilised with CY + G-CSF or standard chemotherapy + G-CSF Results are expressed as mean ± standard deviation.
densation, cytoplasmic blebbing, reduction in cell volume to form apoptotic bodies, and endonuclease cleavage of DNA into oligonucleosomal fragments. Morphologic changes resulting in exposure of phosphatidylserine on the outer membrane surface occur early in the apoptotic process before there is evidence of nuclear condensation, DNA fragmentation or membrane damage.
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We have found a subpopulation of CD34 + progenitor cells from PBSC harvests which bind annexin V. In the majority of harvests at least one in five of the progenitor cell population was annexin V+ and in several harvests at least 50% of CD34 + cells were annexin V+. The harvests were analysed immediately following collection and before cryopreservation which may have affected cell viability. Therefore, these results should give an accurate account of the progenitor cell status in the peripheral circulation following mobilisation. There were no apparent differences in the harvesting or mobilisation regimens to explain the wide variation in annexin V positivity observed. Although the group of patients had received different types of first-line treatment prior to mobilisation, this did not appear to influence the size of the apoptotic cell fraction. In one patient, who received no prior treatment and was mobilised with G-CSF alone, 51% of CD34 + cells stained with annexin V. Analysis of annexin V staining on CD34
+ cells did not correlate with the use of either CY or standard chemotherapy in the mobilisation regimen. CY did produce a significant increase in CD34 + cells and clonogenic cells (CFU-GM). The type of chemotherapy used in G-CSF supported mobilising regimens has been reported to influence the quantity and antigenic profile of PBSC. 22, 23 Staining cells with 7-AAD is an alternative method for quantifying apoptotic cells by flow cytometry 15 Using this stain, significantly less CD34
+ cells were apoptotic in G-CSF-mobilised PBSC compared with unstimulated peripheral blood CD34 + cells. 24 The proportion of CD34 + cells staining with 7-AAD was less than the proportion of CD34 + cells that stained with annexin V in our harvests. This may be due to differences in treatment prior to mobilisation or to differences in the analysis technique, 7-AAD stains DNA by passing through the cell membrane whereas annexin V binds directly to the cell membrane undergoing conformational changes.
A comparison of consecutive harvests found no significant difference in the collection of CD34 + progenitor cells or clonogenic cells. A significantly higher proportion of CD34 + progenitor cells from the first harvest stained with annexin V FITC. There was no obvious explanation for this observation, but it would not appear to be influenced by the use of cytotoxic drugs for mobilisation. In a patient who received G-CSF alone, 51% of CD34 + cells were apoptotic in the first harvest. This decreased to 15% by the third harvest but there was also a reduction in the total number of CD34 cells collected from 4.5 × 10 6 /kg in the first harvest to 1.3 × 10 6 /kg in the third harvest. Changes in the progenitor cell population have been reported in consecutive harvests. A decrease in a subpopulation of CD34 + Thy-1 + cells indicate that more primitive progenitor cells are released earlier during the recovery phase and are lost through successive apheresis. 22 This is supported by an increased CFU-GM count with consecutive harvests. 25 The CFU-GM assay measures committed progenitor cells not expressing Thy-1.
Analysis of annexin V binding introduces a qualitative factor to the quantitative analysis of CD34 + cells by flow cytometry. Previously, the quality of bone marrow harvests or apheresis products was measured by CFU-GM assay, inherent in this culture procedure was a measure of the viability of the progenitor cells. With the development of MoAb to differentiation antigens, flow cytometry, using markers such as CD34 has largely replaced clonogenic assays. Although these two assays measure different biological phenomena, many reports have sought to establish a linear relationship between them. 23, [26] [27] [28] No definitive conclusions could be drawn from our study on transplanting patients with harvests containing a high proportion of apoptotic CD34
+ cells as only four of the patients were transplanted. Further clinical studies are indicated to determine if the apoptotic status of progenitor cells may influence the success of engraftment.
There may be important implications for a graft that contains a high proportion of CD34 + cells that are annexin V+. These progenitor cells have exposed phosphatidylserine on their outer cell membrane which acts as a recognition signal for macrophages to phagocytose apoptotic cells. 17 This is a common mechanism removing unwanted cells without promoting tissue damage resulting from the lysis of dead cells. It seems likely that following reinfusion, annexin V+ progenitor cells may be subject to recognition and removal by macrophages. Whether increased levels of annexin V positivity seen in this study are peculiar to circulating CD34 + cells and not to BM-derived cells requires further study. Annexin V binding by circulating progenitor cells may be an early signal of their elimination from the haematopoietic system.
In conclusion, the addition of annexin V FITC to CD34 PE-stained PBSC samples can identify, using dual colour flow cytometry, a population of progenitor cells which are under going apoptosis. On average, one fifth of CD34 + cells stained with annexin V and the analysis provided additional information on progenitor cell viability following mobilisation and collection. It may be useful to evaluate the apoptotic status of progenitor cells before beginning ex vivo manipulation procedures such as stem cell expansion or gene therapy.
